Journal
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
Volume 22, Issue 12, Pages 2416-2419Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-13-0680
Keywords
-
Funding
- Intramural Research Program of the NIH, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services
Ask authors/readers for more resources
Helicobacter pylori (H. pylori) seropositivity has been inconsistently associated with pancreatic cancer. We, therefore, investigated the association between H. pylori seropositivity and pancreatic cancer in a case-control study nested within Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC) cohort of Finnish male smokers. Pancreatic cancer cases (n = 353) and control subjects (n = 353) were matched on date of baseline serum collection, age at randomization, and follow-up time (up to 23.9 years). We used a multiplex serology assay to determine the sero-status of antibodies against 15 H. pylori-specific antigens in fasting serum samples. Conditional logistic regression was used to calculate the odds ratio (OR) and 95% confidence intervals (CI). Neither targeted H. pylori antigens in serum nor the combination of all was associated with development of pancreatic cancer (combination of all: OR, 0.85; 95% CI, 0.49-1.49). Our results suggest that H. pylori is not a risk factor for pancreatic cancer. (C) 2013 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available